Contract With Customer, Maximum Accepted Product

No definition available.

Name:	rxrx_ContractWithCustomerMaximumAcceptedProduct
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer, Number Of Novel Small Molecule Candidates

+ References

No definition available.

+ Details

Name:	rxrx_ContractWithCustomerNumberOfNovelSmallMoleculeCandidates
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Performance Obligation, Number Of Obligations

+ References

No definition available.

+ Details

Name:	rxrx_RevenuePerformanceObligationNumberOfObligations
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated

+ References

No definition available.

+ Details

Name:	rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated
Namespace Prefix:	rxrx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	rxrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-SubTopic 10
-Topic 808
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479428/808-10-45-3

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=rxrx_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_MilestoneTypeAxis=rxrx_ResearchMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_MilestoneTypeAxis=rxrx_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rxrx_MerckKGaAMerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_MilestoneTypeAxis=rxrx_DiscoveryDevelopmentAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsCreationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsRawImagesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_DevelopedAndCommercializedProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_GastrointestinalCancerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_NeuroscienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Development Contracts (Details) $ in Millions	1 Months Ended					3 Months Ended		9 Months Ended		57 Months Ended
Collaborative Development Contracts (Details) $ in Millions	Oct. 31, 2025 USD ($)	Apr. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($) performance_obligation	Jan. 31, 2022 USD ($) program performance_obligation phenomap candidate	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized						$ 5.6	$ 4.5	$ 17.0	$ 36.6
Sanofi \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum number of novel small molecule candidates \| candidate					15
Remaining unearned revenue					$ 100.0
Revenue from milestone for a potential first-in-class		$ 10.0
Revenue recognized										$ 44.0
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation					8
Remaining performance obligation revenue					$ 166.0
Sanofi \| Collaborative Arrangement \| Research Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining unearned revenue					555.0
Sanofi \| Collaborative Arrangement \| Development And Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining unearned revenue					1,800.0
Merck KGaA (Merck) \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining unearned revenue				$ 20.1
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation				3
Remaining performance obligation revenue				$ 20.1
Merck KGaA (Merck) \| Collaborative Arrangement \| Discovery, Development And Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining unearned revenue				$ 73.0
Roche and Genentech \| Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Remaining unearned revenue					$ 150.0
Revenue recognized	$ 30.0		$ 30.0
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation					3
Remaining performance obligation revenue					$ 210.0
Roche and Genentech \| Collaborative Arrangement \| Phenomaps Creation
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research project, fees and milestones payments receivable for an option on a lead series					$ 250.0
Number of eligible phenomaps \| phenomap					16
Roche and Genentech \| Collaborative Arrangement \| Phenomaps Raw Images
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research project, fees and milestones payments receivable for an option on a lead series					$ 250.0
Number of eligible phenomaps \| phenomap					12
Roche and Genentech \| Collaborative Arrangement \| Developed and Commercialized Programs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research project, fees and milestones payments receivable for an option on a lead series					$ 300.0
Number of projects that may be initiated \| program					40
Roche and Genentech \| Collaborative Arrangement \| Gastrointestinal Cancer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation					1
Roche and Genentech \| Collaborative Arrangement \| Neuroscience
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations under the agreement (in performance obligations) \| performance_obligation					2